ANTITUMOR AGENT Russian patent published in 2022 - IPC A61K31/4245 A61K31/45 C07D271/06 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics and concerns sulfonamide compounds for the treatment and/or prevention of tumors. For this purpose, a pharmaceutical composition is developed, containing the effective amount of a sulfonamide compound represented by the formula (I), where X¹ is an oxygen atom; X² is an oxygen atom; X³ is -NH-; X⁴ is a hydrogen atom; R¹ is -C(R¹¹)(R¹²)-; one of R¹¹ and R¹² is a hydrogen atom, and the other is a methyl group; R² is a phenyl group having R²¹ as a substituent; R²¹ is a halogen atom or C1-C6 alkyl group (when two or more of R²¹ are present, R²¹ are the same or different from each other); R³ is a phenyl group having R³¹ as a substituent, or a chromanyl group having Rc as a substituent; R³¹ is a halogen atom or an aminocarbonyl group (when two or more of R³¹ are present, R³¹ are the same or different from each other ); Rc is a halogen atom, a hydroxy group, or C1-C6 alkyl group (when two or more of Rc are present, Rc are the same or different from each other), and R⁴ is a hydrogen atom; or its pharmaceutically acceptable salt and at least another antitumor agent. An agent for enhancing the antitumor effect of another antitumor agent, an antitumor agent for the treatment of a cancer patient receiving another antitumor agent, a sulfonamide compound, and methods for the treatment and/or prevention of cancer are also disclosed.

EFFECT: resulting compounds have the activity of inhibiting ribonucleotide reductase (RNR) and enhance the antitumor effect when used together with another compound having an antitumor effect.

36 cl, 4 dwg, 51 tbl, 355 ex